Quick Summary:
Emerging in the nexus of advanced medical science and the alarming rise of chronic diseases, the Global Therapeutic Plasma Exchange Market offers essential revenue channels and opportunities for both healthcare providers and biopharma corporations. Therapeutic plasma exchange (TPE) or plasmapheresis—an innovative procedure for extracting pathogenic substances from patients' blood, holds significant market potential driven by its broad application across various ailments, from autoimmune disorders to renal and hematological conditions.
Its core competence rests in its therapeutic benefit of reducing plasma viscosity and managing chronic diseases. Furthermore, advances in technological precision have improved the efficacy of the procedure, seen in the development of next-gen apheresis devices and continuous-flow centrifugation, escalating application scope and market attractiveness. Therapeutic plasma exchange's increasing utility as the primary treatment for diverse neurological conditions such as acute inflammatory demyelinating polyradiculoneuropathy and myasthenia gravis (MG) also significantly contributes to market expansion. Its role in treating a wide range of diseases intensifies the demand for TPE, potentially boosting the overall market growth trajectory.
However, despite the promising market landscape, it's critical to address inherent market challenges such as risks associated with plasmapheresis procedures and the heightened costs of specialized equipment and compliance with strict industry standards. Nevertheless, opportunities await in the continuous advancement of blood processing technology and burgeoning scope for pediatric applications. Armed with this holistic market analysis, stakeholders can strategically navigate the evolving Therapeutic Plasma Exchange market landscape.
Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Therapeutic plasma exchange (TPE), also known as plasmapheresis, is an advanced medical procedure used to separate pathogenic substances from patients' blood and replace them with replacement fluids, such as albumin solution or fresh frozen plasma. These substances include infective autoantibodies, immune complexes, cryoglobulins, and cholesterol-containing lipoproteins. TPE is widely employed in the treatment of various autoimmune conditions, renal disorders, hematological disorders, and more, contributing significantly to market expansion. It also offers the significant benefit of reducing plasma viscosity and is utilized in the management of chronic diseases as a first-line or second-line therapy or as a supportive treatment. During plasma exchange, a substantial portion of plasma containing toxins and other abnormal matter is extracted from the other blood components and replaced with replacement fluid, such as fresh frozen plasma (FFP) or albumin.
Key Market Drivers:
1. High Prevalence of Neurological, Renal, and Hematological Disorders: The high prevalence of chronic diseases, including nephrological disorders, acute liver failure, Guillain-Barré Syndrome (GBS), and others, contributes to the growth of the overall therapeutic plasma exchange market. There has been a surge in the application of therapeutic plasma exchange, accompanied by intensive research and clinical trials to assess its efficacy compared to other treatments. These factors significantly bolster the growth of the therapeutic plasma exchange market.2. Advances in Therapeutic Plasma Exchange Research and Development: High-precision technologies like continuous-flow centrifugation effectively separate specific blood components, and technological advancements, including the development of next-generation apheresis devices, are being observed. Advanced TPE systems minimize manual intervention, enhance procedure efficiency, and promote the adoption of such systems for a wide range of conditions.
3. Expanding Variety of Therapeutic Plasma Exchange Applications: The treatment of a wide array of neurological disorders serves as a significant catalyst for market growth. TPE is considered the primary treatment for conditions such as acute inflammatory demyelinating polyradiculoneuropathy, myasthenia gravis (MG), and paraneoplastic encephalopathies. Additionally, it is employed as a secondary treatment for various other neurological conditions. The prevalence of these neurological disorders continues to rise, contributing to market progress.
4. Increasing Demand for Source Plasma from Biopharmaceutical Companies: The growing demand for source plasma from biopharmaceutical companies for the treatment of various debilitating, chronic, and life-threatening disorders is a significant driver. Plasma-derived therapies play a crucial role in the treatment of a broad spectrum of diseases, contributing to the demand for plasma-derived products and the growth of the plasmapheresis market.
Key Market Challenges:
1. Risk Associated with Plasmapheresis Procedures: Plasmapheresis procedures involve extracting a portion of blood from the human body and administering replacement fluids intravenously. While generally considered safe, there are associated risks, including infection, allergic reactions, hypotension, internal bleeding, electrolyte imbalance, and others. These risks may limit the widespread adoption of plasmapheresis.2. High Cost of Therapeutic Plasma Exchange Products: The cost of specialized equipment required for therapeutic plasma exchange, such as apheresis machines and disposable components, contributes to the high cost of the procedure. Quality control processes and compliance with industry standards further add to the cost. The limited scale of production for TPE products can also lead to higher per-unit costs.
Key Market Trends:
1. Continuous Advancement: Ongoing technological advancements enhance patient satisfaction and improve the processing of blood-derived goods. Advanced methods like continuous-flow centrifugation require minimal blood flow, making them more advanced for facilitating blood collection. These technological developments create opportunities within the market.2. Use of Therapeutic Plasma Procedure in Pediatric Applications: Therapeutic plasma exchange treatments are increasingly studied for pediatric applications in the removal of pathogenic materials in various diseases. This includes the treatment of rare pediatric disorders and autoimmune diseases, contributing to market growth.
Segmental Insights:
1. Indication Insights: Neurological disorders are expected to dominate the market, driven by the increasing incidence and prevalence of these diseases in the geriatric population and ongoing research in this field.2. Technology Insights: Centrifugation technology is projected to hold a significant share in the Therapeutic Plasma Exchange market, thanks to its widespread adoption in donor apheresis, offering cost-effectiveness and efficient plasma removal.
Regional Insights: North America dominates the global therapeutic plasma exchange market, with factors such as a high prevalence of autoimmune diseases, a well-established hospital infrastructure, and a strong presence of biotech enterprises contributing to its growth.
Key Market Players
- Asahi Kasei Corporation
- Baxter International Inc
- B. Braun Melsungen AG
- Cerus Corporation
- Fresenius Kabi AG
- Haemonetics Corporation
- Hemacare Corporation
- IncMedica S.p.A.
- Kawasumi Laboratories
- Terumo Corporation
Report Scope:
In this report, the Global Therapeutic Plasma Exchange Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:Therapeutic Plasma Exchange Market, By Product:
- Consumables
- Devices
Therapeutic Plasma Exchange Market, By Technology:
- Centrifugation
- Membrane Separation
Therapeutic Plasma Exchange Market, By Indication:
- Neurological Disorders
- Haematology Disorders
- Renal Disorders
- Metabolic Disorders
- Others
Therapeutic Plasma Exchange Market, By End User:
- Blood Collection Centres & Blood Component Providers
- Hospitals & Clinics
- Blood Transfusion Centres
- Others
Therapeutic Plasma Exchange Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Turkey
- Egypt
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Therapeutic Plasma Exchange Market.Available Customizations:
Global Therapeutic Plasma Exchange market report with the given market data, the publisher offers customizations according to a company's specific needs.This product will be delivered within 1-3 business days.
What is the estimated value of the rapeutic Plasma Exchange Market?
What is the growth rate of the rapeutic Plasma Exchange Market?
What is the forecasted size of the rapeutic Plasma Exchange Market?
Who are the key companies in the rapeutic Plasma Exchange Market?
Report Attribute | Details |
---|---|
No. of Pages | 188 |
Published | October 2023 |
Forecast Period | 2023 - 2028 |
Estimated Market Value ( USD | $ 762.01 Million |
Forecasted Market Value ( USD | $ 1111.6 Million |
Compound Annual Growth Rate | 6.7% |
Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- Asahi Kasei Corporation
- Baxter International Inc
- B. Braun Melsungen AG
- Cerus Corporation
- Fresenius Kabi AG
- Haemonetics Corporation
- Hemacare Corporation
- IncMedica S.p.A.
- Kawasumi Laboratories
- Terumo Corporation